Connect with us

Hi, what are you looking for?

Jewish Business News


3 Stock Picks From Mario Gabelli

On CNBC, Mario Gabelli discussed three stocks that are on his radar.

Mario Gabelli


Diebold (DBD) trades at around $38, and Gabelli sees a potential 50% rise in the stock if the company executes its turnaround well. The company beat earnings estimates by 7 cents, but missed on revenue estimates, although these increased by 3.7% year over year. Diebold has undergone a management shuffle and is streamlining costs. Sales have been dropping in North America, but there was improvement in gross margins on the service side of the business. Orders in Latin America jumped 5%. Those who are bullish on the stock emphasize the strength of the company’s turnaround prospects and its dividend increases.

Chemtura (CHMT) is another turnaround story Gabelli likes, and he thinks it could offer 100% return in the next 5 years. Chemtura missed earnings estimates on July 29th by 3 cents and its revenue came in $14.6 million short of estimates, although this was a 3.2% rise from last year. Chemtura bulls note it is spinning off assets to become a company more focused on specialty chemicals. It recently announced it would sell off its AgroSolutions business to generate cash and improve its balance sheet.

Weatherford (WFT) is another company Gabelli praises for reorganizing. It is increasing its buyback, paying off debt, and Halliburton (HAL) will become a 50% owner of the company. WFT beat earnings estimates by 3 cents, but its revenues declined 4.7%. It is selling off its Russian and Venezuelan rigs to Rosneft in a $500 million deal.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...


Now Platika joins and elite club of $10 billion plus Israeli firms.